Identification of medical products


The building blocks of IDMP implementation

Unlock the power of data to transform business and improve patient health

Meeting IDMP requirements is a complex process, with many moving parts. Efficient and effective implementation will require companies to develop a vision and global IDMP strategy to drive alignment, collaboration, and cooperation.

The building blocks of IDMP implementation

The potential benefits of meeting evolving Identification of Medicinal Product (IDMP) requirements extend far beyond regulatory compliance. Through IDMP implementation, pharmaceutical companies can unlock the power of product data to transform their business and improve patient health. Download the full report to learn more.

Collecting this data is expected to:

  • Link product and safety information across global regulatory agencies
  • Increase the biopharma industry’s signal detection capabilities to quickly identify product risk issues, including recalls
  • Connect critical product information within health care systems
  • Help facilitate the creation of global drug dictionaries and product dossiers
View or download the report

IDMP five standards

IDMP is a set of five data standards from the International Organization for Standardization. Under the IDMP standards, pharmaceutical and biotech companies will be required to electronically submit detailed product data and maintain it on an ongoing basis.

Five standards of IDMP

IDMP timeline

The IDMP timeline has been dynamic; in the European Union clarity is starting to emerge. The United States and other markets should expect to see increasing activity over the next few years.  

Becoming IDMP-compliant is expected to drive biopharma organisations to make significant changes to current product-related processes and systems, ushering in a new era of cross-functional collaboration and paving the way for opportunities to generate transformational benefits beyond compliance.

Additionally, the European Medicines Agency (EMA) is engaging in efforts to drive regulatory standardization for core IDMP master data governing Substance, Product, Organization and Referential (SPOR) data, for which a subset will also be expected to be leveraged in other EU directives, further making IDMP implementation critical. This article addresses the challenges and opportunities of IDMP implementation and describes a path forward for biopharma companies.

Learn about how companies can take a first and most crucial step towards achieving IDMP readiness through a thorough and diligent fit-gap analysis.

Did you find this useful?